Navigation Links
Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
Date:5/25/2011

LONDON, May 25, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in London, UK.

Results from Primary Dosing Period and Ongoing Extension of Phase 2b Combination Study with Allopurinol

Results presented from the ongoing blinded extension portion of Ardea's Phase 2b study (study 203) of lesinurad in patients who did not achieve target on allopurinol therapy alone demonstrated that for those patients who have reached week 28 of the extension period, 91 percent of those patients receiving lesinurad in combination with allopurinol achieved serum urate (sUA) levels below the clinically important target of 6 mg/dL.  Importantly, continued reductions in sUA were observed beyond the initial 28 days of dosing with a majority of the responding patients remaining on a 200 mg dose of lesinurad thus far in the extension period.  These preliminary results are from the extension portion of a 28-day, randomized, double-blind, placebo-controlled Phase 2b study evaluating lesinurad in combination with allopurinol in 208 gout patients with elevated sUA greater than or equal to 6 mg/dL who were not adequately responding despite being on a stable dose of allopurinol.  Following the 28-day primary dosing period and at least a two-week washout, 126 patients entered the optional extension period and restarted dosing with 200 mg of lesinurad or placebo.  Non-responding patients can be escalated up to 400 mg or 600 mg of lesinurad, at the investigators' discretion.  Currently, 30 patients have been dosed for at least 6 m
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013 Advanced Prenatal Therapeutics (APT), ... that will help alleviate the high blood pressure and ... is expected to be the first medical device specifically ... and fetal death. Every year, preeclampsia affects ... States . It is characterized by high blood ...
(Date:5/22/2013)... May 22, 2013 Attorney Advertising -- Bronstein, ... on behalf of purchasers of the securities of ... AMAG -News).  The investigation focuses on whether the ... On May 22, 2013, Shares of ... after the company announced in regulatory filing that ...
(Date:5/22/2013)... , May 22, 2013  The Leukemia & Lymphoma ... to Valor Biotherapeutics, LLC, a joint venture between ImmunGene ... manufacturing, and a Phase I clinical trial for a ... faced by many patients with indolent lymphomas who do ... Valor,s protein, IGN002, is a new class of ...
Breaking Medicine Technology:Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia 2Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4
... PARSIPPANY, N.J., Jan. 31, 2011 PDI, Inc. (Nasdaq: ... officer, is scheduled to present at the UBS 21st Annual Global ... at the Grand Hyatt New York. The live ... company,s website at http://www.pdi-inc.com . The webcast will be archived ...
... Calif., Jan. 31, 2011 OXIS International, Inc., (OTC ... today announced highly favorable final results from an initial ... patent-pending ERGOFLEX™ joint health formula, launched commercially ... of pain was statistically significant after as little as ...
Cached Medicine Technology:Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 2Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 3Final Results from ERGOFLEX Study Show Statistically Significant Reduction in Joint Pain in as Little as One Week 4
(Date:5/22/2013)... that bicyclists who wear helmets have an 88 percent ... Children,s Hospital found that simply having bicycle helmet laws ... and injuries for children younger than 16 who were ... study, conducted by William P. Meehan III, MD, Lois ... of Boston Children,s Hospital, and Christopher M. Fischer, MD, ...
(Date:5/22/2013)... MD (PRWEB) May 22, 2013 On a ... Lisa, spent a few hours watching “The Bourne Legacy” at ... While this may seem like a typical activity to many ... This little stretch of respite from their everyday reality has ... Seals Serving DC | MD | VA. , Life changed ...
(Date:5/22/2013)... The Muscular Dystrophy Association scored a huge ... annual Charlotte Muscle Team event held May 21 by ... with muscle disease. , "The Charlotte community really ... families,” said MDA Divisional Director Theresa Miller. “From the ... "Buddy" to make their night extra special, to the ...
(Date:5/22/2013)... Reporter , , WEDNESDAY, May 22 (HealthDay News) -- People ... likely to attempt suicide, whether or not they also ... a new study. "Clinicians who are seeing patients ... at increased risk of suicide," said study co-author Mark ... Resource and Evaluation Center in Ann Arbor, Mich. ...
(Date:5/22/2013)... Cedar Rapids, IA (PRWEB) May 22, 2013 ... inspirational theatre piece Handicap This! The performance promotes ... pursuing their dreams. The Handicap This! performance will be ... Linn Mar High School auditorium. Tickets for Handicap ... , Handicap This! helps audiences measure the level to ...
Breaking Medicine News(10 mins):Health News:Rate of bicycle-related fatalities significantly lower in states with helmet laws 2Health News:Military Family Finds Respite with Easter Seals 2Health News:Military Family Finds Respite with Easter Seals 3Health News:Charlotte Muscle Team Event Raises $300,000 in the Fight Against Muscle Disease 2Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 2Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 3Health News:Handicap This! Comes to Marion, Iowa 2
... ... ... Advocate Christ Medical Center and Hope Children’s Hospital was awarded the Morehead Apex Workplace ... the Ritz-Carlton in Charlotte, N.C. , , ,Christ Medical Center and Hope Children’s Hospital ...
... lead to new birth control for men , WEDNESDAY, April ... proteins called PLA2s play a vital role in sperm function ... The findings could improve understanding of male infertility and lead ... infertility. , In one study, Japanese researchers found that the ...
... ... except if the girls in the salon chair are battling cancer or other serious illness. Then, ... ... at the Tipperary Hair Salon in Beverly Hills, California, approximately 35 such girls and their sisters ...
... ... District to Develop a 100 Percent Lead Free Bubbler Retrofit Kit , ... Los Angeles, CA (Vocus) April 28, 2010 -- ... and chillers and a division of Acorn Engineering Company, announces a 100 percent lead-free bubbler ...
... 28, 2010 Many of the world,s leading experts in ... first-of-its-kind conference in Kansas City to change the way childhood ... hosted by Children,s Mercy Hospitals and Clinics, is to apply ... unique make-up of pediatric patients and improve outcomes. ...
... ... about supporting you after the sale when you believe you need to return an item. ... with complete confidence knowing that their purchase can be returned for a replacement or a ... ...
Cached Medicine News:Health News:Advocate Christ Medical Center Presented The 2009 Morehead Apex Workplace of Excellence Award 2Health News:Advocate Christ Medical Center Presented The 2009 Morehead Apex Workplace of Excellence Award 3Health News:Pediatric Patients and Siblings Enjoy Beverly Hills Beauty Makeover 2Health News:Pediatric Patients and Siblings Enjoy Beverly Hills Beauty Makeover 3Health News:The Acorn Aqua's Lead Free Bubbler 2Health News:Advances in personalized medicine take center stage 2Health News:National Allergy Supply, The Allergy Products Company Recommended By More Than 9,500 Doctors Nationwide, Announces 100% Unconditional Satisfaction Guarantee 2
... wide range of miniTHERM incubators is available, ... application solution for their specific requirements. miniTHERM ... are compact and extremely space saving. Their ... oven. It is possible to stack up ...
... range of miniTHERM incubators is available, ensuring ... solution for their specific requirements. miniTHERM incubators ... compact and extremely space saving. Their size ... It is possible to stack up to ...
... resistance of stainless steel with the ... offers an electro-polished copper-alloy-stainless interior that ... sterile environment promotes the integrity of ... safety of laboratory staff. This exclusive ...
US Autoflow Single Chamber Stackable Water-Jacketed CO2 Inc.w/ Humidity Display and Control...
Medicine Products: